Neurology

health news

Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)

Staff November 27, 2023

Conference call today at 8:30 am ETVANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a...

Read MoreRead more about Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
health news

GE HealthCare Showcases More Than 40 Innovations, Including AI-Enabled Imaging Technology Solutions Designed for Precision Care at RSNA23

Staff November 26, 2023

Booth (#7326) will highlight new product introductions, key innovations, and AI-enabled advancements from the company’s comprehensive portfolio of Imaging, Ultrasound,...

Read MoreRead more about GE HealthCare Showcases More Than 40 Innovations, Including AI-Enabled Imaging Technology Solutions Designed for Precision Care at RSNA23
health news

Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

Staff November 20, 2023

Median overall survival (mOS) in 15 patients with recurrent glioblastoma (rGBM) from the Phase 2 study is 13 months, which...

Read MoreRead more about Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
health news

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

Staff November 20, 2023

LA JOLLA, Calif., Nov. 19, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market...

Read MoreRead more about MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
health news

CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism

Staff November 14, 2023

Results From Landmark Study Published in Brain JournalCollaborative research initiative leveraged CENTOGENE’s Whole Exome Sequencing (WES) to reveal disease-causing gene...

Read MoreRead more about CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism
health news

CORRECTION BY SOURCE: The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis

Staff November 10, 2023

This corrects and replaces the release that was disseminated earlier todayLack of OHE-specific diagnostic code in hospitals may increase risk...

Read MoreRead more about CORRECTION BY SOURCE: The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
health news

The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis

Staff November 10, 2023

Lack of OHE-specific diagnostic code in hospitals may increase risk of additional cost, length of hospitalization and additional burdens for...

Read MoreRead more about The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
health news

Pharma Two B Announces Publication of Positive Phase 3 Study Results of P2B001, an Investigational Treatment for Early Parkinson’s Disease, in Movement Disorders

Staff November 9, 2023

Demonstrated that P2B001 provides benefits comparable with commercially used doses of marketed pramipexole-ER (PramiER) while minimizing associated daytime sleep–related and...

Read MoreRead more about Pharma Two B Announces Publication of Positive Phase 3 Study Results of P2B001, an Investigational Treatment for Early Parkinson’s Disease, in Movement Disorders
health news

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Staff November 9, 2023

-- Blocking of α5β1 integrin has been shown to improve motor function and increase survival in the SOD1G93A mouse model of...

Read MoreRead more about Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

You may have missed

health news

CorePlus Puerto Rico Publishes Groundbreaking Study on Implementing 100% Quality Control in Cervical Cytology Using Whole Slide Imaging and Artificial Intelligence

Staff May 28, 2025
health news

AirStrip® Introduces Alarm Management: A Game-Changing FDA Approved Integrated Platform Transforming Clinical Alarm Management of Vital Signs

Staff May 27, 2025
health news

Rapid Dose Announces Proposed Equity Private Placement Financing

Staff May 27, 2025
health news

AI-Powered Wearable Cuts Cancer Deaths by 90%— Redefines Infection Detection in Chemotherapy

Staff May 27, 2025
health news

Awakn Life Sciences Announces Completion of Arrangement and Sale to Solvonis Therapeutics plc

Staff May 27, 2025
error: Content is protected !!